Viale M, Ferrini S, Bacigalupo A
Istituto Nazionale per la Ricerca sul Cancro (IST), Servizio di Farmacologia, Genova, Italy.
Bone Marrow Transplant. 1992 Sep;10(3):249-53.
Peripheral gamma/delta+ T cells were studied in patients following allogeneic bone marrow transplantation (BMT) by indirect immunofluorescence utilizing two monoclonal antibodies (G1 and A13) able to recognize the two major subpopulations (V delta 2+ and V delta 1+, respectively) of these cells. We found that the relative percentage of 'total' (gamma/delta+ T lymphocytes) (V delta 2 + V delta 1 positive cells), and particularly of G1+ (V delta 2+) cells, in CD3+ lymphocytes was higher in transplanted patients, and especially in those presenting with acute graft-versus-host disease (aGVHD), than in normal controls. This finding was confirmed by the analysis of the V delta 2+/V delta 1+ cell ratio which was again significantly higher in patients with aGVHD as compared to controls. Similarly, the absolute number of 'total' gamma/delta+ and V delta 2+ cells was also significantly increased in patients with aGVHD. TCR gamma/delta+ T cells increased as a function of time after BMT reaching a plateau value at about day 60 post-BMT. When patients were stratified for the presence or absence of aGVHD this correlation was maintained only for patients with aGVHD. Finally, most V delta 2+ cells expressed surface T cell activation markers such as CD25 (IL-2 receptor) and DR (MHC class II) antigens. Our results suggest a possible involvement of gamma/delta+ T cells and particularly of V delta 2+ cells in the clinical and immunological events (aGVHD) occurring after allogeneic BMT.
利用两种能够识别外周血γ/δ⁺ T细胞两个主要亚群（分别为Vδ2⁺和Vδ1⁺）的单克隆抗体（G1和A13），通过间接免疫荧光法对异基因骨髓移植（BMT）后的患者外周血γ/δ⁺ T细胞进行了研究。我们发现，移植患者CD3⁺淋巴细胞中“总”（γ/δ⁺ T淋巴细胞）（Vδ2⁺ + Vδ1⁺阳性细胞），尤其是G1⁺（Vδ2⁺）细胞的相对百分比高于正常对照组，在患有急性移植物抗宿主病（aGVHD）的患者中更是如此。通过分析Vδ2⁺/Vδ1⁺细胞比例证实了这一发现，与对照组相比，aGVHD患者的该比例同样显著更高。同样，aGVHD患者中“总”γ/δ⁺和Vδ2⁺细胞的绝对数量也显著增加。TCR γ/δ⁺ T细胞在BMT后随时间增加，在BMT后约60天达到平台值。当根据是否存在aGVHD对患者进行分层时，这种相关性仅在患有aGVHD的患者中保持。最后，大多数Vδ2⁺细胞表达表面T细胞活化标志物，如CD25（IL-2受体）和DR（MHC II类）抗原。我们的结果表明，γ/δ⁺ T细胞，尤其是Vδ2⁺细胞可能参与了异基因BMT后发生的临床和免疫事件（aGVHD）。
